SWP
NVIV

Stratos Wealth Partners’s InVivo Therapeutics Holdings Corp NVIV Stock Holding History

Stratos Wealth Partners’s Portfolio NVIV Stock Details NVIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-400
Closed -$7K – 1322
2021
Q3 		$7K Hold
400
– – ﹤0.01% 1180
2021
Q2 		$7K Hold
400
– – ﹤0.01% 1187
2021
Q1 		$10K Buy
+400
New +$12K ﹤0.01% 1115

Other funds holding NVIV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Stratos Wealth Partners's NVIV Position: Q4 2021 in Review

Stratos Wealth Partners sold out of InVivo Therapeutics Holdings Corp (NVIV) in Q4 2021, closing a stake of 400 shares — an estimated $7K sold.

Stratos Wealth Partners first reported a position in NVIV in Q1 2021 and held it in 3 quarters. The position peaked at $10K in Q1 2021. 19 funds tracked by Wall St. Rank hold NVIV as of Q4 2021.

  • Stratos Wealth Partners reported no remaining InVivo Therapeutics Holdings Corp position as of Q4 2021 after selling out during the quarter.
  • Stratos Wealth Partners sold 400 InVivo Therapeutics Holdings Corp shares in Q4 2021, an estimated $7K.
  • Stratos Wealth Partners first reported a position in InVivo Therapeutics Holdings Corp in Q1 2021 and held it in 3 quarters.
  • Stratos Wealth Partners's InVivo Therapeutics Holdings Corp position peaked at $10K in Q1 2021.
  • 19 funds tracked by Wall St. Rank held InVivo Therapeutics Holdings Corp as of Q4 2021.

Based on Stratos Wealth Partners's 13F filing for Q4 2021, filed 14 Jan 2022.